Resensitizing daclatasvir-resistant hepatitis C variants by allosteric modulation of NS5A

[1]  Sebastian Lambert,et al.  The crystal structure of NS5A domain 1 from genotype 1a reveals new clues to the mechanism of action for dimeric HCV inhibitors , 2014, Protein science : a publication of the Protein Society.

[2]  N. Meanwell,et al.  HCV NS5A replication complex inhibitors. Part 4. Optimization for genotype 1a replicon inhibitory activity. , 2014, Journal of medicinal chemistry.

[3]  M. Desai,et al.  Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection. , 2014, Journal of medicinal chemistry.

[4]  N. Meanwell,et al.  Characterizations of HCV NS5A replication complex inhibitors. , 2013, Virology.

[5]  J. Pawlotsky.  NS5A inhibitors in the treatment of hepatitis C. , 2013, Journal of hepatology.

[6]  F. Mcphee,et al.  Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors. , 2013, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[7]  J. McCarville,et al.  1209 TREATMENT-EMERGENT VARIANTS FOLLOWING 3 DAYS OF MONOTHERAPY WITH IDX719, A POTENT, PAN-GENOTYPIC NS5A INHIBITOR, IN SUBJECTS INFECTED WITH HCV GENOTYPES 1–4 , 2013 .

[8]  A. Flaxman,et al.  Global epidemiology of hepatitis C virus infection: New estimates of age‐specific antibody to HCV seroprevalence , 2013, Hepatology.

[9]  Libin Rong,et al.  Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life , 2013, Proceedings of the National Academy of Sciences.

[10]  J. Lemm,et al.  Effect on Hepatitis C Virus Replication of Combinations of Direct-Acting Antivirals, Including NS5A Inhibitor Daclatasvir , 2012, Antimicrobial Agents and Chemotherapy.

[11]  Yugang Liu,et al.  Asymmetric synthesis of α-amino acids by reduction of N-tert-butanesulfinyl ketimine esters. , 2011, The Journal of organic chemistry.

[12]  M. Poss,et al.  A Novel Small Molecule Inhibitor of Hepatitis C Virus Entry , 2010, PLoS pathogens.

[13]  Min Gao,et al.  Resistance Analysis of the Hepatitis C Virus NS5A Inhibitor BMS-790052 in an In Vitro Replicon System , 2010, Antimicrobial Agents and Chemotherapy.

[14]  Min Gao,et al.  Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect , 2010, Nature.

[15]  M. Hickey,et al.  Crystal Structure of a Novel Dimeric Form of NS5A Domain I Protein from Hepatitis C Virus , 2009, Journal of Virology.

[16]  Y. Tanabe,et al.  Practical and robust method for the preparation of seebach and Fráter's chiral template, cis-2-substituted 5-methyl(or phenyl ) -1,3 -dioxolan -4 -ones , 2006 .

[17]  Ralf Bartenschlager,et al.  Quantitative Analysis of the Hepatitis C Virus Replication Complex , 2005, Journal of Virology.

[18]  Colin W Shepard,et al.  Global epidemiology of hepatitis C virus infection. , 2005, The Lancet. Infectious diseases.

[19]  C. Rice,et al.  Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase , 2005, Nature.

[20]  Volker Brass,et al.  Structure and Function of the Membrane Anchor Domain of Hepatitis C Virus Nonstructural Protein 5A* , 2004, Journal of Biological Chemistry.

[21]  Mark Harris,et al.  Hepatitis C virus NS5A: tales of a promiscuous protein. , 2004, The Journal of general virology.

[22]  R. Bartenschlager,et al.  Characterization of Cell Lines Carrying Self-Replicating Hepatitis C Virus RNAs , 2001, Journal of Virology.

[23]  R. Palmiter,et al.  Complete hepatic regeneration after somatic deletion of an albumin-plasminogen activator transgene , 1991, Cell.

[24]  D. Seebach,et al.  (α-Alkylation of α-heterosubstituted carboxylic acids without racemization : EPC-syntheses of tertiary alcohols and thiols☆☆☆ , 1984 .